Milvexian Fails to Cut Recurrent Ischemic Events When Added After Acute Coronary Syndrome
Start here
Adding milvexian, an oral factor XIa inhibitor, to standard antiplatelet therapy within 7 days after an acute coronary syndrome did not reduce recurrent ischemic events, a trial in the New England Journal of Medicine reports. In 14,194 patients followed for a median of 12.2 months, the composite of cardiovascular death, myocardial infarction, or ischemic stroke occurred in 5.4% of patients on milvexian versus 5.1% on placebo (hazard ratio, 1.05; 95% CI, 0.91 to 1.21). The trial was stopped for futility at a planned interim analysis. Major bleeding, the key safety concern for anticoagulant addition, was rare and identical in both groups at 0.3%, leaving open whether factor XIa inhibition can find a role in other cardiovascular settings.
Written by a model from the reports · updated 3 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- nejm.orgPickRole for Factor XIa Inhibitors after an Acute Coronary Syndrome Event
The article examines the role of Factor XIa inhibitors after an acute coronary syndrome event. The available information consists only of the New England Journal of Medicine volume, issue, page numbers and date; it does not specify a drug, clinical trial, sample size, efficacy endpoints, or safety results.
- N Engl J MedPickMilvexian with Antiplatelet Therapy after Acute Coronary Syndrome Event.
Adding milvexian, an oral factor XIa inhibitor, to standard antiplatelet therapy within 7 days after an acute coronary syndrome did not reduce recurrent ischemic events. In 14,194 patients followed for a median of 12.2 months, the composite of cardiovascular death, myocardial infarction, or ischemic stroke occurred in 5.4% with milvexian versus 5.1% with placebo (hazard ratio, 1.05; 95% CI, 0.91 to 1.21). The trial was stopped for futility at a planned interim analysis; major bleeding rates were 0.3% in both groups.
Heat trend for this story
Not enough continuous observation yet to draw a trend.